NO941310D0 - Sammensetning og fremgangsmåte for behandling av hepatitt C - Google Patents

Sammensetning og fremgangsmåte for behandling av hepatitt C

Info

Publication number
NO941310D0
NO941310D0 NO941310A NO941310A NO941310D0 NO 941310 D0 NO941310 D0 NO 941310D0 NO 941310 A NO941310 A NO 941310A NO 941310 A NO941310 A NO 941310A NO 941310 D0 NO941310 D0 NO 941310D0
Authority
NO
Norway
Prior art keywords
thymosin
hepatitis
treatment
composition
immune system
Prior art date
Application number
NO941310A
Other languages
English (en)
Norwegian (no)
Other versions
NO941310L (no
Inventor
Paul Chretian
Milton Mutchnick
Kenneth E Sherman
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Kenneth E Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick, Kenneth E Sherman filed Critical Alpha 1 Biomedicals Inc
Publication of NO941310L publication Critical patent/NO941310L/no
Publication of NO941310D0 publication Critical patent/NO941310D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
NO941310A 1991-09-13 1994-04-12 Sammensetning og fremgangsmåte for behandling av hepatitt C NO941310D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (2)

Publication Number Publication Date
NO941310L NO941310L (no) 1994-04-12
NO941310D0 true NO941310D0 (no) 1994-04-12

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941310A NO941310D0 (no) 1991-09-13 1994-04-12 Sammensetning og fremgangsmåte for behandling av hepatitt C

Country Status (23)

Country Link
US (3) US6001799A (cs)
EP (1) EP0603305B1 (cs)
JP (1) JP3228512B2 (cs)
KR (1) KR100254082B1 (cs)
AT (1) ATE152914T1 (cs)
AU (1) AU667327B2 (cs)
CA (1) CA2119006C (cs)
CZ (1) CZ286827B6 (cs)
DE (1) DE69219782T2 (cs)
DK (1) DK0603305T3 (cs)
ES (1) ES2103966T3 (cs)
FI (1) FI107879B (cs)
GR (1) GR3024025T3 (cs)
HK (1) HK1021687A1 (cs)
HU (1) HU221006B1 (cs)
MX (1) MX9205240A (cs)
NO (1) NO941310D0 (cs)
RO (1) RO111991B1 (cs)
RU (1) RU2104010C1 (cs)
SG (1) SG64897A1 (cs)
TW (1) TW224053B (cs)
WO (1) WO1993005806A1 (cs)
ZA (1) ZA926964B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU4671193A (en) * 1992-07-13 1994-01-31 Kenneth E. Sherman Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
CA2175337C (en) * 1993-11-05 2000-06-20 Paul B. Chretien Method and composition for treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
ES2160927T3 (es) * 1996-02-28 2001-11-16 Unihart Corp Composiciones farmaceuticas que comprenden interferon alfa humano natural.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN101099745A (zh) 2000-05-26 2008-01-09 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
KR100851861B1 (ko) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
CN1564693A (zh) * 2001-10-05 2005-01-12 印特缪恩股份有限公司 治疗肝纤维化和丙型肝炎病毒感染的方法
ES2299626T3 (es) * 2001-10-26 2008-06-01 Rhode Island Hospital Aumento de timosina para asegurar una inmunizacion genetica.
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
DE602004027127D1 (de) * 2003-03-28 2010-06-24 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
CA2520400C (en) 2003-03-28 2013-02-19 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ES2586668T5 (es) 2003-05-30 2024-11-12 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
JP2007501185A (ja) 2003-07-25 2007-01-25 イデニクス（ケイマン）リミテツド Ｃ型肝炎を含むフラビウイルス関連疾患を治療するためのプリンヌクレオシド類似体
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
HRP20120676T1 (hr) * 2006-05-02 2012-09-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
AR074977A1 (es) 2008-12-23 2011-03-02 Pharmasset Inc Sintesis de nucleosidos de purina
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
AU2011235112B2 (en) 2010-03-31 2015-07-09 Gilead Sciences, Inc. Nucleoside phosphoramidates
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
CN105517540B (zh) 2013-08-27 2019-08-23 吉利德制药有限责任公司 两种抗病毒化合物的复方制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
NO941310L (no) 1994-04-12
CZ55194A3 (en) 1994-10-19
AU2644792A (en) 1993-04-27
JP3228512B2 (ja) 2001-11-12
GR3024025T3 (en) 1997-10-31
US6001799A (en) 1999-12-14
ZA926964B (en) 1993-04-26
TW224053B (cs) 1994-05-21
AU667327B2 (en) 1996-03-21
FI107879B (fi) 2001-10-31
MX9205240A (es) 1993-07-01
RU2104010C1 (ru) 1998-02-10
DE69219782T2 (de) 1997-10-09
RO111991B1 (ro) 1997-04-30
RU94022480A (ru) 1996-07-20
JPH06510998A (ja) 1994-12-08
ES2103966T3 (es) 1997-10-01
DE69219782D1 (de) 1997-06-19
EP0603305A1 (en) 1994-06-29
CZ286827B6 (cs) 2000-07-12
FI941133A0 (fi) 1994-03-10
CA2119006C (en) 2005-08-23
CA2119006A1 (en) 1993-04-01
HU221006B1 (hu) 2002-07-29
FI941133L (fi) 1994-03-10
US5849696A (en) 1998-12-15
HK1021687A1 (en) 2000-06-23
KR100254082B1 (ko) 2000-09-01
HU9400758D0 (en) 1994-06-28
WO1993005806A1 (en) 1993-04-01
EP0603305B1 (en) 1997-05-14
HUT75166A (en) 1997-04-28
SG64897A1 (en) 1999-05-25
US20070218033A1 (en) 2007-09-20
ATE152914T1 (de) 1997-05-15
DK0603305T3 (da) 1997-09-01

Similar Documents

Publication Publication Date Title
NO941310D0 (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
EP0717592A4 (en) METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
AU4205789A (en) Method and composition for the treatment and prevention of viral infections
NO951340L (no) Fremgangsmåte til å behandle lungesykdom med uridintrifosfater
ITTO940713A0 (it) Vaccino per la prevenzione della sindrome riproduttiva e respiratoria porcina.
FI943028L (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
ATE196849T1 (de) Verfahren zur behandlung von multiplesklerose
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
EP0325129A3 (en) Disubstituted pyridines
FI924363A0 (fi) Foerfarande foer behandling och/eller diagnostisering av mjukvaevnadstumoerer.
FI941705A0 (fi) Menetelmä viruspatogeenien läpipääsyn estämiseksi
GB9109478D0 (en) Antivenoms
NO910219L (no) Behandling av tre og trebaserte materialer.
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
DE3884652D1 (de) Gate-Ausschaltthyristor und Verfahren zu dessen Herstellung.
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
NO933628D0 (no) Fremgangsmaate og blanding for behandling av herpes-infeksjoner
MY110041A (en) Composition and method of treating hepatitis c
DK0497356T3 (da) Sammensætninger og fremgangsmåde til tumorer i blødt væv
NO961775D0 (no) Fremgangsmåte og sammensetning for behandling av pasienter med dekompensert leversykdom
ZA897105B (en) Method and composition for the treatment of viral infections
NO911595L (no) Fremgangsmaate og enhet til haandtering av skrotter.
NO903504L (no) Doseringsbeholder for opptak og levering av midler for behandling av toey.
NO930550L (no) Metode og preparat for behandling av virale infeksjoner